


# The world needs an AIDS vaccine.

From our founding in 1995, IAVI has been unwavering in a commitment to developing an HIV vaccine that is safe, accessible, and effective. While scientific understanding of HIV, the trajectory of the epidemic, and the prevention and treatment environment have evolved, we have remained steadfast in our belief that ending AIDS will require a vaccine.

More than three decades of progress against the AIDS epidemic demand that IAVI contribute to global research efforts in new ways. Expanded use of antiretroviral drugs and novel prevention methods such as male circumcision and pre-exposure prophylaxis remind us that an effective vaccine will stand alongside other, vital tools that reduce infections, lower viremia, and improve and prolong life for people living with HIV. To realize IAVI's ultimate aspiration—the complete elimination of AIDS—we must catalyze the entire field of HIV research. Our 2017-2021 Strategic Plan is predicated upon the understanding that progress toward an AIDS vaccine requires insights gleaned from other prevention innovations, basic, translational, and clinical research partners, and community participants. By integrating scientific investigation, product development, clinical research, and a commitment to partnership, IAVI's Strategic Plan strives to expedite the availability of a vaccine and other biomedical innovations to prevent HIV infection and save millions of lives.

To reach these objectives, IAVI's efforts will be aligned around four pillars:



## **ENGAGE LOCALLY**

*Enhance country and community engagement in areas most at risk for HIV*

The search for an AIDS vaccine must begin and end with populations most at risk of HIV infection and most in need of prevention options. Through ethical and culturally sensitive research, IAVI staff will pursue answers that will make us a more informed scientific partner. How will vulnerable groups identify and accept new prevention technologies? How do virologic and epidemiologic changes shape the epidemic's future trajectory? How can IAVI strengthen scientific capacity in Africa and India for present and future generations of investigators? Understanding the needs of local populations will be critical to designing, developing, and delivering prevention products with the fewest obstacles to access and the greatest potential for impact.

## **CATALYZE INNOVATIVE SCIENCE**

*Invest in high-potential programs, partnerships, and platforms*

HIV vaccine research has made important inroads over the years. However, to optimize that scientific promise and hasten its translation into life-saving products, we must continue to facilitate the state-of-the-art vaccine discovery and translational research of investigators within and outside of IAVI. Committed to inventive approaches for collaboration, IAVI scientists will share knowledge across sectors, expend energy to form new and productive partnerships, answer unmet needs, and look beyond HIV for insights and technologies that reveal unexpected platforms to expedite the development of an effective HIV vaccine.

## ACCELERATE TRANSLATION

### *Advance innovative concepts into promising candidates*

Building upon the expertise of our vaccine development team, IAVI will focus on pioneering approaches to speed the translation of promising concepts from the lab to early phase clinical testing in order to evaluate their potential and inform future vaccine design optimization. By creating an iterative framework for development, we seek to enable HIV vaccine research to operate with greater efficiency and to provide the broader prevention research field with tools to prioritize products and inform global stakeholders which candidates hold the greatest hope to protect against infection.

## SECURE SUSTAINED SUPPORT AND ACTION

### *Enhance evidence-based advocacy research to help maintain HIV/AIDS funding as a global priority*

By promoting understanding of the treatment and prevention landscape, IAVI will emphasize the urgency of controlling the AIDS pandemic by all means available. We will communicate that antiretroviral treatment must be paired with new biomedical approaches to prevention, and that governments, civil society, and the private sector must stimulate the innovation that can generate those approaches. By articulating the evidence base documenting the importance of more effective HIV prevention tools, IAVI will support the productivity and effectiveness of the field and hasten the day when highly effective HIV prevention innovations are available to bring the pandemic to an end.

Each of these pillars is linked to a robust series of programs conducted by IAVI and our partners around the world. Each program has a monitoring, evaluation, and learning component that enables us to measure progress against the Strategic Plan and ensure increased capacity among IAVI's staff and the field at large.

Although our paramount goal is to expedite the advancement of promising HIV vaccine candidates, IAVI will support the discovery, translation, evaluation of and advocacy for other HIV prevention technologies, and explore ways our capacity and experience can further global health efforts beyond HIV.

Embracing scientific potential within and outside of our doors, IAVI is intent upon energizing the field of biomedical HIV prevention. Our end-to-end product development capabilities, unyielding commitment to advancing the most promising ideas in HIV prevention, and capacity to draw knowledge from communities most vulnerable to HIV, position us to make an unmistakable difference in realizing the vision of a world without AIDS.



IAVI gratefully acknowledges the generous support provided by the following major donors



Bill & Melinda Gates Foundation | Broadway Cares/Equity Fights AIDS | The City of New York, Economic Development Corporation | EMMES Corporation | European Union | Foundation for the National Institutes of Health | The Gilead Foundation | GlaxoSmithKline | Google Inc. | Government of Japan | The Hearst Foundations | Irish Aid, Department of Foreign Affairs and Trade | James B. Pendleton Charitable Trust | Korean Women against AIDS | Ministry of Foreign Affairs of Denmark | Ministry of Foreign Affairs of The Netherlands | Ministry of Science & Technology, Government of India | National Institute of Allergy and Infectious Diseases | Norwegian Ministry of Foreign Affairs | Robert Wood Johnson Foundation | The Starr Foundation | U.K. Department for International Development | The U.S. President's Emergency Plan for AIDS Relief through the U.S. Agency for International Development | The World Bank

*And many other generous individuals from around the world*

As of January 2017



[iavi.org](http://iavi.org)



[info@iavi.org](mailto:info@iavi.org)